Skip to main content
SpringerLink
Log in

HER-2/neu Assessment in Breast Cancer by Immunohistochemistry and Fluorescence In Situ Hybridization: Comparison of Results and Correlation With Survival

  • Original Research
  • Published:
Molecular Diagnosis Aims and scope Submit manuscript

Abstract

Background: HER-2/neu immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) results guide breast cancer therapy; however, few studies compared the results and no published studies have correlated them with patient outcome.

Methods and Results: We compared results, cost, and turnaround time in 117 archival, invasive breast carcinomas and compared 50-month survival in 65 of these cases using commercial HER-2/neu IHC and FISH assays. Twenty-one of 112 FISH (19%) and 33 of 117 IHC cases (28%) were positive. Concordance was high overall (88%; 98 of 112 cases) and in IHC 3+ cases (88%; 14 of 16 cases) but low in IHC 2+ cases (35%; six of 17 cases). Survival correlated with IHC results in 3+ cases (P =.02) and FISH cases with signal ratio greater than 4.0 (P =.03), but not in IHC 2+ cases (P =.7). Cost and turnaround time were greater for FISH.

Conclusion: IHC is appropriate for initial HER-2/neu assessment; however, patients with tumors scored less than 3+, particularly those interpreted as 2+, would benefit from FISH to more accurately assess HER-2/neu status and avoid inaccurate prognostication and inappropriate treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wisecarver JL: Her-2/neu testing comes of age. Am J Clin Pathol 1999; 111:299–301

    PubMed  CAS  Google Scholar 

  2. Ross JS, Fletcher JA: HER-2/neu gene and protein in breast cancer. Am J Clin Pathol 1999;112(Suppl 1): S53–S67

    PubMed  CAS  Google Scholar 

  3. Slamon DJ, Godolphin W, Jones LA, et al.: Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–712

    Article  PubMed  CAS  Google Scholar 

  4. Press MF, Pike MC, Chazin VR, et al.: Her-2/neu expression in node negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960–4970

    PubMed  CAS  Google Scholar 

  5. Depowski PL, Brien TP, Sheehan CE, et al.: Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and Her-2 gene amplification detected by fluorescence in situ hybridization in breast cancer. Am J Clin Pathol 1999;112: 459–469

    PubMed  CAS  Google Scholar 

  6. Press MF, Bernstein L, Thomas PA, et al: Her-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15: 2894–2904

    PubMed  CAS  Google Scholar 

  7. Noguchi M, Koyasaki N, Ohta N, et al.: C-erbB-2 oncoprotein expression versus internal mammary lymph node metastasis as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 1992,69:2953–2960

    Article  PubMed  CAS  Google Scholar 

  8. Hartmann LC, Ingle JN, Wold LE, et al.: Prognostic value of c-erbB-2 overexpression in axillary lymph node-positive breast cancer: Results from a randomized adjuvant treatment protocol. Cancer 1994;74: 2956–2963

    Article  PubMed  CAS  Google Scholar 

  9. Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of Her-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63–72

    PubMed  CAS  Google Scholar 

  10. McGuire WL: Adjuvant therapy of node negative breast cancer. N Engl J Med 1989;320:525–527

    Article  PubMed  CAS  Google Scholar 

  11. Thor AD, Berry DA, Budman DR, et al.: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90:1346–1360

    Article  PubMed  CAS  Google Scholar 

  12. Pegram MD, Lipton A, Hayes DF, et al.: Phase 2 study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER-2/neu monoclonal antibody plus cisplatin in patients with Her-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659–2671

    PubMed  CAS  Google Scholar 

  13. Baselga J, Norton L, Albanell J, et al.: Recombinant humanized anti-Her-2/neu antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against Her-2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825–2831

    PubMed  CAS  Google Scholar 

  14. Tiwari RK, Borgen PL, Wong GY, et al.: HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 1992;12:419–425

    PubMed  CAS  Google Scholar 

  15. Paik S, Bryant J, Park C, et al.: ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361–1370

    Article  PubMed  CAS  Google Scholar 

  16. Carlomagno C, Perrone F, Gallo C, et al.: c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastasis. J Clin Oncol 1996;14: 2702–2708

    PubMed  CAS  Google Scholar 

  17. Borg A, Baldetorp B, Ferno M, et al.: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994;81:137–144

    Article  PubMed  CAS  Google Scholar 

  18. Slamon D, Leyland-Jones B, Shak S, et al.: Addition of Herceptin (humanized anti HER2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer (HER+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc ASCO 1998; 17:98A (abstr)

    Google Scholar 

  19. Stal O, Sullivan S, Wingreen S, et al.: C-erb B-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995;31A:2185–2190

    Article  PubMed  CAS  Google Scholar 

  20. Tetu B, Brisson J, Plante V, et al.: p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol 1998;11:822–830

    Google Scholar 

  21. Tetu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359–2365

    Article  PubMed  CAS  Google Scholar 

  22. Press MF, Hung G, Godholphin W, Slamon DJ: Sensitivity of Her-2/neu antibodies in archival samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54:2771–2777

    PubMed  CAS  Google Scholar 

  23. Jacobs TW, Gown AM, Yaziji H, et al.: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999:17:1983–1987

    PubMed  CAS  Google Scholar 

  24. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Comparison of fluorescent in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999;7:1974–1982

    Google Scholar 

  25. Couturier J, Nicolas A, Beuzeboc P, et al.: High correlation between ERBB2 amplification detected by FISH and gene overexpression detected by immunohistochemistry in breast cancers. Mod Pathol 1999;12:18A (abstr)

    Google Scholar 

  26. Ashfaq R, Frenkel E, Saliger F, Thomas S, Saboorian MH: HER-2/neu oncogene overexpression: Comparison of immunohistochemistry with fluorescent in situ hybridization assay. Mod Pathol 1999;12:15A (abstr)

    Google Scholar 

  27. Jimenez RE, Wallis T, Tabaczka P, Visscher DW: Fluorescent in situ hybridization vs immunohistochemistry for determination of Her-2/neu status in breast cancer. Mod Pathol 1999;12:23A (abstr)

    Google Scholar 

  28. Kay EW, Walsh CJ, Cassidy M, et al.: C-erbB2 immunostaining: Problems with interpretation. J Clin Pathol 1994;47:816–822

    Article  PubMed  CAS  Google Scholar 

  29. Roche PC, Ingle JN: Increased HER2 with US Food and Drug Administration-approved antibody. J Clin Oncol 1999;17:434 (letter)

    PubMed  CAS  Google Scholar 

  30. Ewer MS, Gibbs HR, Swafford J, Benjamin RS: Cardiotoxicity in patients receiving transtuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 1999;26(Suppl 12):96–101

    PubMed  CAS  Google Scholar 

  31. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol 2000;113:251–258

    CAS  Google Scholar 

  32. Persons DL, Bui MM, Lowery MC, et al.: Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: A multi-center portability study. Ann Clin Lab Sci 2000;30: 41–48

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Illinois at Chicago, 1819 West Polk St, Chicago, Illinois, 60612

    Sanjay Kakar MD, Nick Puangsuvan, Jane M. Stevens MS,MT(ASCP)SM, Romualda Serenas MT(ASCP)I, George Mangan BS, Shalini Sahai MD & Michael L. Mihalov MD

Authors
  1. Sanjay Kakar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nick Puangsuvan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jane M. Stevens MS,MT(ASCP)SM
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Romualda Serenas MT(ASCP)I
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. George Mangan BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shalini Sahai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michael L. Mihalov MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael L. Mihalov MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kakar, S., Puangsuvan, N., Stevens, J.M. et al. HER-2/neu Assessment in Breast Cancer by Immunohistochemistry and Fluorescence In Situ Hybridization: Comparison of Results and Correlation With Survival. Molecular Diagnosis 5, 199–207 (2000). https://doi.org/10.1007/BF03262077

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262077

Keywords

Search

Navigation